Compare State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF vs TG Therapeutics Inc — how do they compare? State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.9, while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: TG Therapeutics Inc is trading nearer its 52-week high, State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF nearer its low. Which is the better fit depends on your goals.
| SJNK | TGTX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $25.63 | $59.06 |
52-Week Low | $24.75 | $26.39 |
Market Cap | — | $8.26B |
Enterprise Value | — | $8.50B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
